NCT05932966Completed

Comparison With Observational Methods and Performance Assessment From Real-life Experience of Closed-Loop Insulin Delivery Systems

Source: ClinicalTrials.gov · Last updated 15 Aug 2024

Brief summary (registry, in English)

This study aims to compare glycemic control obtained under closed loop depending on the system : Smartguard (Medtronic 780) versus Control IQ (Tandem) in patients with diabetes type 1.

Status (registry): Completed
Study type: Observational
Enrollment: 317 (actual)
First submitted: 21 Jun 2023
Start date: 6 Jul 2023
Primary completion date: 11 Jul 2024
Lead sponsor: Centre Hospitalier Sud Francilien
Diseases: Type 1 diabetes
NCT number: NCT05932966

What you commit to

Study type: Observational
Participants enrolled: 317
From 6 Jul 2023 to the primary completion date, 11 Jul 2024
1 site in 1 country
Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

Patient who have been treated with both systems within 12 months.

Other

Women who had pregnancy within 12 months of system initiation.
Patient or parental authority objecting the use of data

Who the study is looking for

Patient \> 16 years
Patient with diabetes type 1.
Patient treated with a CONTROL-IQ or SMARTGUARD closed-loop insulin delivery system between 01/2021 and 05/2022.
Follow-up patient in Centre Hospitalier Sud Francilien

Age in the registry: 16 years to - · Sex: All

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

Site	City	Country	Site status
Centre Hospitalier Sud Francilien Coordinator of this site? Confirm its status	Corbeil-Essonnes	France	Unknown status

This page is information, not medical advice. Discuss any trial with your doctor.